By Colin Kellaher
Nurix Therapeutics has won a key U.S. Food and Drug Administration designation for its lead asset bexobrutideg in a rare type of non-Hodgkin's lymphoma.
Nurix on Monday said the FDA granted orphan-drug designation to bexobrutideg, also known as NX-5948, for the treatment of Waldenstrom macroglobulinemia, a slow growing type of non-Hodgkin's lymphoma characterized by the replacement of normal bone marrow cells by malignant lymphocytic cells.
The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S. It also provides for an extended marketing exclusivity period against competition.
Nurix, a San Francisco clinical-stage biopharmaceutical company, is evaluating bexobrutideg in a Phase 1 study in patients with relapsed or refractory B cell malignancies.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 17, 2025 07:59 ET (11:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。